Search Results

MC# 18-26
A Phase I/II Study of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

MC# 19-37
A Phase Ib, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

MC# 19-39
An Open Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-573 in Adult Patients with Metastatic Solid Tumors; A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study

MC# 18-17
A Phase I Study of RGX-202, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts

MC# 18-23
A Phase II, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours.

MC# 19-26
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination with Rucaparib in Patients with Advanced Breast, Ovarian, or Prostate Cancer

MC# 19-31
A Phase I, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab

MC# 19-25
A Phase I open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

MC# 20-06
A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors

MC# 18-02
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects with Solid Tumors and Non-Hodgkin’s Lymphoma

MC# 19-36
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced/Metastatic Solid Tumors who are refractory to Available Standard Therapies

MC# 19-35
A Phase I/II Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MC# 20-13
An Open-label Phase 1b/2a Study of NT-I7 (Hyleukin-7) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors

MC# 19-02
A Phase I Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

MC# 18-24
A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and/or Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

MC# 19-17
A Phase I, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

MC# 20-15
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors

MC# 19-07
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors

MC# 19-08
A Phase I Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors

MC# 17-36
First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (enapotamab vedotin,HuMax®-AXL-ADC) in Patients with Solid Tumors

MC# 16-07
An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

MC# 16-09
A Phase I Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

MC# 17-33
A Sequential 2-arm, Open-label Phase I Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors

MC# 17-24
A Phase I Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas